CD203c is overexpressed on neoplastic mast cells in systemic mastocytosis and is upregulated upon IgE receptor cross-linking

International Journal of Immunopathology and Pharmacology

Volumn 21, Issue 4, 2008, Pages 797-806

  Hauswirth, A W ^a   Escribano, L ^b   Prados, A ^b   Nunez R ^b   Mirkina, I ^a,c   Kneidinger, M ^a   Florian, S ^a   Sonneck, K ^a   Vales, A ^a   Schernthaner, G H ^a   Sanchez Munoz L ^b   Sperr, W R ^a,c   Buhring H J ^d   Orfao, A ^e   Valent, Peter ^a,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e Centro de Investigacion del Cancer   (Spain)

Author keywords

CD203c; E NPP3; IgE receptor; Mast cells; Mastocytosis

Indexed keywords

CD203C ANTIGEN; ECTONUCLEOTIDEPYROPHOSPHATASE PHOSPHODIESTERASE 3 ECTOENZYME; IMMUNOGLOBULIN E RECEPTOR; MEMBRANE ANTIGEN; MESSENGER RNA; STEM CELL FACTOR; UNCLASSIFIED DRUG;

AGRESSIVE SYSTEMIC MASTOCYTOSIS; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CELL SELECTION; CONTROLLED STUDY; CROSS LINKING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MAST CELL; MAST CELL LEUKEMIA; MASTOCYTOSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMIC MASTOCYTOSIS; SYSTEMIC MASTOCYTOSIS ASSOCIATED HEMATOLOGIC CLONAL NON MAST CELL LINEAGE DISEASE; UPREGULATION;

EID: 59849123132     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200802100404     Document Type: Article

References (33)

1. Lennert K, Parwaresch MR. Mast cells and mast cell neoplasia: a review. Histopathology 1979; 3:349-65.
2. Metcalfe DD. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol 1991; 96:2S-4S.
3. Valent P. Biology, classification and treatment of human mastocytosis. Wien Klin Wochenschr 1996; 108:385-97.
4. Valent P, Akin C, Sperr WR, Horny HP, Arock M, Lechner K, et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 2003; 122:695-717.
5. Akin C, Metcalfe DD. Systemic mastocytosis. Annu Rev Med 2004; 55:419-32.
6. Escribano L, Akin C, Castells M, Orfao A, Metcalfe DD. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol 2002; 81:677-90.
7. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci (USA) 1995; 92:10560-4.
8. Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG, et al. Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996; 12:312-4.
9. Longley BJ, Metcalfe DD, Tharp M, Wang X, Tyrrell L, Lu SZ, et al. Activating and dominant inactivating c-kit catalytic domain mutations in distinct forms of human mastocytosis. Proc Natl Acad Sci (USA) 1999; 96:1609-14.
10. Fritsche-Polanz R, Jordan JH, Feix A, Sperr WR, Sunder-Plassmann G, Valent P, et al. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol 2001; 113:357-64.
11. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006; 108:2366-72.
12. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of the c-kit product. J Clin Invest 1993; 92:1736-44.
13. Valent P, Homy H-P, Escribano L, Longley BJ, Li CY, Schwartz LB, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Conference Report of "Year 2000 Working Conference on Mastocytosis". Leuk Res 2001; 25:603-25.
14. Valent P, Horny H-P, Li CY, et al. Mastocytosis (Mast cell disease). World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. eds: Jaffe ES, Harris NL, Stein H, Vardiman JW. 2001; 1:291-302.
15. Escribano L, Orfao A, Diaz-Agustin B, Diaz-Agustin B, Cervero C, Rios A, et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood 1998; 91:2731-6.
16. Escribano L, Diaz-Agustin B, Bellas C, Navalon R, Nunez R, Sperr WR, et al. Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leuk Res 2001; 25:563-70.
17. Nunez-Lopez R, Escribano L, Schernthaner GH, Prados A, Rodriguez Gonzalez R, Diaz Agustin B, et al. Overexpression of complement receptors and related antigens on the surface of bone marrow mast cells in patients with systemic mastocytosis. Br J Haematol 2003; 120:257-65.
18. Schernthaner GH, Jordan JH, Ghannadan M, Agis H, Bevec D, Nunez R, et al. Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. Blood 2001; 98:3784-92.
19. Valent P, Schernthaner GH, Sperr WR, Fritsch G, Agis H, Willheim M, et al. Variable expression of activation-linked surface antigens on human mast cells in health and disease. Immunol Rev 2001; 179:74-81.
20. Knol EF, Mul FPJ, Jansen H, Calafat J, Roos D. Monitoring human basophil activation via CD63 monoclonal antibody 435. J Allergy Clin Immunol 1991; 88:328-38.
21. Bühring H-J, Simmons PJ, Pudney M, Muller R, Jarrossay D, Agthoven A, et al. The monoclonal antibody 97A6 defines a novel surface antigen expressed on human basophils and their multi- and unipotent progenitors. Blood 1999; 94:2343-56.
22. Bühring HJ, Seiffert M, Giesert C, Marxer A, Kanz L, Valent P, et al. The basophil activation marker defined by antibody 97A6 is identical with ectonucleotide pyrophosphatase/phosphodiesterase 3 (E-NPP3; CD203c). Blood 2001; 97:3303-5.
23. Hauswirth AW, Natter S, Ghannadan M, Majlesi Y, Schernthaner GH, Sperr WR, et al. Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. J Allergy Clin Immunol 2002; 110:102-9.
24. Ghannadan M, Hauswirth AW, Schernthaner GH, Müller MR, Klepetko W, Schatzl G, et al. Detection of novel CD antigens on the surface of human mast cells and basophils. Int Arch Allergy Immunol 2002; 127:299-307.
25. Bühring HJ, Streble A, Valent P. The basophil-specific ectoenzyme E-NPP3 (CD203c) as a marker for cell activation and allergy diagnosis. Int Arch Allergy Immunol 2004; 133:317-29.
26. Valent P, Ashman LK, Hinterberger W, Eckersberger F, Majdic O, Lechner K, et al. Mast cell typing: demonstration of a distinct hematopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes. Blood 1989; 73:1778-85.
27. Sotlar K, Horny HP, Simonitsch I, Krokowski M, Aichberger KJ, Mayerhofer M, et al. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 2004; 28:1319-25.
28. Butterfield JH, Weiler D, Dewald G, Gleich GJ. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res 1988; 12: 345-55.
29. Sillaber C, Strobl H, Bevec D, Ashman LK, Butterfield JH, Lechner K, et al. IL-4 regulates c-kit proto-oncogene product expression in human mast and myeloid progenitor cells. J Immunol 1991; 147: 4224-8.
30. Mirkina I, Schweighoffer T, Kricek F. Inhibition of human cord blood-derived mast cell responses by anti-Fc epsilon RI mAb 15/1 versus anti-IgE Omalizumab. Immunol Lett 2007; 109:120-8.
31. Escribano L, Diaz-Agustin B, Lopez A, Nunez Lopez R, Garcia-Montero A, Almeida J, et al. Spanish Network on Mastocytosis (REMA). Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA). Cytometry B Clin Cytom 2004; 58:1-8.
32. Wimazal F, Krauth MT, Vales A, Böhm A, Agis H, Sonneck K, et al. Immunchistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category. Leuk Lymphoma 2006; 47:451-60.
33. Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, Brockow K, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37:435-53.